Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 225 record(s)

Req # A-2022-000977

Adverse Drug Reaction (ADR). Report number: E2B_05647389.

Organization: Health Canada

25 page(s)
January 2023

Req # A-2022-000985

Adverse Drug Reactions (ADRs) for . Report numbers: E2B_05162489, 001000230.

Organization: Health Canada

233 page(s)
January 2023

Req # A-2022-000987

Adverse Drug Reactions (ADRs) for Zenhale. Report numbers: E2B_00037157, E2B_00356618, E2B_01322347, E2B_01490363, E2B_01388080, E2B_01401854, E2B_01413472, E2B_01430853, E2B_01443157, E2B_01494497.

Organization: Health Canada

2689 page(s)
January 2023

Req # A-2022-000989

Adverse Drug Reaction (ADR). Report number: E2B_05593659.

Organization: Health Canada

15 page(s)
January 2023

Req # A-2022-001000

Adverse Drug Reactions (ADRs). Report numbers: 001005965, E2B_04565185.

Organization: Health Canada

44 page(s)
January 2023

Req # A-2022-001002

Adverse Drug Reaction (ADR) for MEZAVANT. Report number: E2B_05680477. ADRs for Mesalazine. Report numbers: 001006029, 001006464, E2B_05628348, E2B_05643268. ADRs for VYVANSE. Report numbers: 001005158, E2B_05661529, 001005967. ADRs for GAMMAGARD LIQUID. Report numbers: 001011490, 001008161.

Organization: Health Canada

197 page(s)
January 2023

Req # A-2022-001004

Adverse Drug Reactions (ADRs) for C1 Esterase Inhibitor (Human). Report numbers: E2B_05697513, E2B_05662863, E2B_05676847. ADRs for Immunoglobulin (human). Report numbers: E2B_05654955, E2B_05650332, E2B_05626265, E2B_05638123, E2B_05675217. ADR for REPLAGAL. Report number: E2B_05645576. ADR for Lanadelumab. Report number: E2B_05662049.

Organization: Health Canada

139 page(s)
January 2023

Req # A-2022-001005

Adverse Drug Reaction (ADR) for Dexilant. Report number: E2B_05679330. ADR for Entyvio. Report number: E2B_05636147. ADRs for Vedolizumab. Report numbers: E2B_05710173, E2B_05621550, 001006464, E2B_05612446. ADR for Ixazomib. Report number: E2B_05641996. ADR for ADDERALL XR. Report number: 001008189. ADRs for Amphetamine. Report numbers: 001007205, E2B_05661529.

Organization: Health Canada

366 page(s)
January 2023

Req # A-2022-001009

Adverse Drug Reactions (ADRs) for BISACODYL AND DOCUSATE SODIUM. Report numbers: 001006655, 001006867, E2B_05628348, E2B_05657880, E2B_05628332.

Organization: Health Canada

165 page(s)
January 2023

Req # A-2022-001023

Adverse Drug Reactions (ADRs) for Januvia. Report numbers: E2B_02958375, E2B_03435748, E2B_03207281, E2B_03014229, E2B_03480899, E2B_04284040, 000918607, 000650406.

Organization: Health Canada

188 page(s)
January 2023
Date modified: